Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
Microsoft to shut down Skype to shift focus towards Teams platform
The Microsoft-owned service was a pioneer in live video calls but later lost ground to competing programs such as Zoom.
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...
Santé log20h
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...
Patriots head coach Mike Vrabel jabs Travis Hunter, tells prospect he's 'not the only one to play two ways'
T he most unique prospect in recent memory to come through the NFL Draft is Colorado's Travis Hunter. Why? Well, he just ...